Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

Sarah Atkinson, Shannon Lubaczewski, Sara Ramaker, Richard D England, Dalia B Wajsbrot, Richat Abbas, Robert L Findling, Sarah Atkinson, Shannon Lubaczewski, Sara Ramaker, Richard D England, Dalia B Wajsbrot, Richat Abbas, Robert L Findling

Abstract

Objective: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD).

Methods: Outpatient children (7-11 years) and adolescents (12-17 years) who met DSM-IV-TR criteria for MDD and had screening and baseline Children's Depression Rating Scale-Revised (CDRS-R) total scores >40 were randomly assigned to 8 weeks of treatment with placebo, low exposure desvenlafaxine (20, 30, or 35 mg/day based on baseline weight), or higher exposure desvenlafaxine (25, 35, or 50 mg/day based on baseline weight). The primary efficacy endpoint was change from baseline in CDRS-R total score at week 8, analyzed using a mixed-effects model for repeated measures. Secondary efficacy assessments included Clinical Global Impressions-Severity and Clinical Global Impressions-Improvement scales. Safety assessments included adverse events and the Columbia-Suicide Severity Rating Scale.

Results: The safety population included 363 patients (children, n = 109; adolescents, n = 254). No statistical separation from placebo was observed for either desvenlafaxine group for CDRS-R total score or for any secondary efficacy endpoint. At week 8, adjusted mean (standard error) changes from baseline in CDRS-R total score for the desvenlafaxine low exposure, desvenlafaxine high exposure, and placebo groups were -23.7 (1.1), -24.4 (1.1), and -22.9 (1.1), respectively. The incidence of adverse events was similar among groups.

Conclusion: Low and high exposure desvenlafaxine groups did not demonstrate efficacy for the treatment of MDD in children and adolescents in this double-blind, placebo-controlled trial. Desvenlafaxine (20-50 mg/day) was generally safe and well tolerated with no new safety signals identified in pediatric patients with MDD in this study.

Trial registration: ClinicalTrials.gov NCT01371734.

Keywords: adolescents; children; clinical trial; desvenlafaxine; major depressive disorder; treatment efficacy.

Figures

FIG. 1.
FIG. 1.
Study flow and patient disposition ITT. ITT, intent-to-treat.
FIG. 2.
FIG. 2.
Adjusted mean (SE) change from baseline in CDRS-R score in children and adolescents; MMRM analysis, ITT population. *p = 0.013, desvenlafaxine low exposure versus placebo; p = 0.034, desvenlafaxine high exposure versus placebo. Adjusted mean difference vs placebo (95% CI), week 8: desvenlafaxine low exposure, 0.85 (−2.23, 3.94); desvenlafaxine high exposure, 1.52 (−1.56, 4.61). CDRS-R, Children's Depression Rating Scale-Revised; MMRM, mixed-effects model for repeated measures; SE, standard error.

References

    1. Atkinson SD, Prakash A, Zhang Q, Pangallo BA, Bangs ME, Emslie GJ, March JS: A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:180–189, 2014
    1. Birmaher B, Brent D, Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J: Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 46:1503–1526, 2007
    1. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, Perel J, Nelson B: Childhood and adolescent depression: A review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 35:1427–1439, 1996
    1. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA: Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166:42–49, 2009
    1. Carrasco JL, Kornstein SG, McIntyre RS, Fayyad R, Prieto R, Salas M, Mackell J, Boucher M: An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol 31:134–146, 2016
    1. Cheung AH, Zuckerbrot RA, Jensen PS, Ghalib K, Laraque D, Stein RE: Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics 120:e1313–e1326, 2007
    1. Clark MS, Jansen KL, Cloy JA: Treatment of childhood and adolescent depression. Am Fam Physician 86:442–448, 2012
    1. Edwards AC, Joinson C, Dick DM, Kendler KS, Macleod J, Munafo M, Hickman M, Lewis G, Heron J: The association between depressive symptoms from early to late adolescence and later use and harmful use of alcohol. Eur Child Adolesc Psychiatry 23:1219–1230, 2014
    1. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y: Venlafaxine ER for the treatment of pediatric subjects with depression: Results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 46:479–488, 2007
    1. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205–1215, 2002
    1. Emslie GJ, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS: A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:170–179, 2014
    1. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031–1037, 1997
    1. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S: Escitalopram in the treatment of adolescent depression: A randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 48:721–729, 2009
    1. Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, Carpenter DJ, Lipschitz A, Machin A, Wilkinson C: Paroxetine treatment in children and adolescents with major depressive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 45:709–719, 2006
    1. Enck P, Bingel U, Schedlowski M, Rief W: The placebo response in medicine: Minimize, maximize or personalize? Nat Rev Drug Discov 12:191–204, 2013
    1. Fergusson DM, Woodward LJ: Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry 59:225–231, 2002
    1. Findling RL, Groark J, Chiles D, Ramaker S, Yang L, Tourian KA: Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:201–209, 2014
    1. Findling RL, Groark J, Tourian KA, Ramaker SA, Chiles D, Yang L, Nichols AI: Pharmacokinetics and tolerability of single-ascending doses of desvenlafaxine administered to children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 26:909–921, 2016
    1. Guy W: Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, US Department of Health, Education, and Welfare, 1976, pp. 217–222
    1. International Council for Harmonisation: ICH harmonised tripartite guideline: Statistical principles for clinical trials E9. 1998. Accessed May15, 2017
    1. Iwata N, Tourian KA, Hwang E, Mele L, Vialet C, For the Study 3359 Investigators: Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 19:5–14, 2013
    1. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988, 1997
    1. Kobak KA, Leuchter A, Debrota D, Engelhardt N, Williams JB, Cook IA, Leon AC, Alpert J: Site versus centralized raters in a clinical depression trial: Impact on patient selection and placebo response. J Clin Psychopharmacol 30:193–197, 2010
    1. Kobak KA, Lipsitz JD, Williams JB, Engelhardt N, Bellew KM: A new approach to rater training and certification in a multicenter clinical trial. J Clin Psychopharmacol 25:407–412, 2005
    1. Lexapro [package insert]. St. Louis, MO, Forest Pharmaceuticals, Inc., 2014
    1. Liebowitz MR, Tourian KA, Hwang E, Mele L, For the Study 3362 Investigators: A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry 13:94, 2013
    1. Marmorstein NR: Longitudinal associations between alcohol problems and depressive symptoms: Early adolescence through early adulthood. Alcohol Clin Exp Res 33:49–59, 2009
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ: The Columbia-suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266–1277, 2011
    1. Poznanski EO, Freman LN, Mokros HB: Children's depression rating scale-revised (September 1984). Psychopharmacol Bull 21:979–989, 1985
    1. Pristiq [package insert]. Philadelphia, PA, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc., 2016
    1. Prozac [package insert]. Indianapolis, IN, Eli Lilly and Company, 2014
    1. Puig-Antich J, Kaufman J, Ryan ND, Williamson DE, Dahl RE, Lukens E, Todak G, Ambrosini P, Rabinovich H, Nelson B: The psychosocial functioning and family environment of depressed adolescents. J Am Acad Child Adolesc Psychiatry 32:244–253, 1993
    1. Rief W, Barsky AJ, Bingel U, Doering BK, Schwarting R, Wohr M, Schweiger U: Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions. Neurosci Biobehav Rev 60:51–64, 2016
    1. Rutherford BR, Roose SP: A model of placebo response in antidepressant clinical trials. Am J Psychiatry 170:723–733, 2013
    1. Siu AL: Screening for depression in children and adolescents: U.S. preventive services task force recommendation statement. Ann Intern Med 164:360–366, 2016
    1. Targum SD, Wedel PC, Robinson J, Daniel DG, Busner J, Bleicher LS, Rauh P, Barlow C: A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder. J Psychiatr Res 47:944–954, 2013
    1. Temple R, Ellenberg SS: Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 133:455–463, 2000
    1. Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT: An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectrums 14:144–154, 2009
    1. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials. JAMA 290:1033–1041, 2003
    1. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE: A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079–1083, 2004
    1. Walkup JT: Antidepressant efficacy for depression in children and adolescents: Industry- and NIMH-Funded studies. Am J Psychiatry 174: 430–437, 2017
    1. Weihs K, Murphy W, Abbas R, Chiles D, England R, Ramaker S, Wajsbrot DB: Desvenlafaxine vs placebo in a fluoxetine-referenced study of children and adolescents with MDD. J Child Adolesc Psychopharmacol 2017;28:36–46
    1. Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, Klier CM, Ryan ND, Dahl RE, Wickramaratne P: Depressed adolescents grown up. JAMA 281:1707–1713, 1999
    1. Young AS, Meers MR, Vesco AT, Seidenfeld AM, Arnold LE, Fristad MA: Predicting therapeutic effects of psychodiagnostic assessment among children and adolescents participating in randomized controlled trials. J Clin Child Adolesc Psychol, 2016. [Epub ahead of print]. DOI:10.1080/15374416.2016.1146992

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere